丁丙诺啡含片治疗晚期癌痛初始剂量的观察  

Analgesic effect of initial dose of buprenorphine sublingual tablet on terminal cancer pain

作　　者：魏青[1] 王昆[1] 

机构地区：[1]天津医科大学肿瘤医院麻醉科,天津市300060

出　　处：《中国临床康复》2004年第17期3228-3229,共2页Chinese Journal of Clinical Rehabilitation

摘　　要：目的:临床评价初始剂量的丁丙诺啡含片对癌痛的镇痛效果及药物的不良反应。方法:各类型晚期癌症中度顽固性疼痛患者160例,随机分为两组,舌下含服丁丙诺啡含片0.2mg(实验组)80例,0.4mg(对照组)80例,连续用药1周,观察疗效及药物不良反应。结果:丁丙诺啡片用于缓解癌症中度疼痛,初始剂量0.2mg,6～8h/次,可使85%的疼痛患者得到中度以上缓解。丁丙诺啡片药物不良反应主要为头晕、恶心、呕吐等。其发生率0.4mg丁丙诺啡组略高于0.2mg丁丙诺啡组。结论:丁丙诺啡含片对晚期癌痛确有明显镇痛效果,药效维持时间长,且使用方便,不良反应轻,患者容易接受。AIM:To evaluate the analgesic effect of initial dose of buprenorphine sublingual tablet in the clinical treatment of cancer pains and the adverse drug reactions(ADRs). METHODS:Totally 160 patients with moderate intractractadle pain of various terminal cancers were divided into two groups(80 patients in each group):0.2 mg buprenorphine was used in experimental group,and 0.4 mg in control group,both for 1 week.The effects and ADRs of the two groups were observed and compared. RESULTS:Buprenorphine could be used to relieve the moderate cancer pain.A total effective rate of 85%(moderate or above pain) were achieved for patients with over moderate pain after treatment with initial dose of 0.2 mg buprenorphine every 6-8 hours.The main ADRs of buprenorphine were dizziness,nausea and vomiting.The incidence of ADRs was a little higher in the control group than in the experimental group. CONCLUSION:Buprenorphine sublingual tablet with the advantages of little ADRs and easy usage,has obvious analgesic effect on the terminal cancer pain for long duration,so it is easily accepted by patients.

关 键 词：丁丙诺啡含片 药物治疗 晚期癌痛 初始剂量 不良反应 

分 类 号：R730.53[医药卫生—肿瘤] R441.1[医药卫生—临床医学]